Second-line erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): Results from a large, open-label study

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 19002-19002
Author(s):  
L. Crinò ◽  
M. Boyer ◽  
W. E. Eberhardt ◽  
Z. Balikó ◽  
E. F. Smit
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 9045-9045 ◽  
Author(s):  
Jonathan Wade Goldman ◽  
Jean-Charles Soria ◽  
Heather A. Wakelee ◽  
D. Ross Camidge ◽  
Shirish M. Gadgeel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Biomarker analyses from an open-label study of erlotinib in advanced non-small-cell lung cancer (NSCLC)

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 19012-19012
Author(s):  
N. van Zandwijk ◽  
W. Su ◽  
R. Rooneem ◽  
B. Mehi|Dc ◽  
F. A. Franke
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document